Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308133723> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4308133723 endingPage "A69" @default.
- W4308133723 startingPage "A69" @default.
- W4308133723 abstract "Abstract Introduction It has been shown that complement factors are increased in polycystic ovary syndrome (PCOS) and that these may be affected by obesity and insulin resistance. Hypothetically, this may increase cardiometabolic risk but, paradoxically, increased clotting is not a feature of PCOS. To investigate this, proteomic analysis of the complement system was undertaken, including inhibitory proteins. Methods Plasma was collected from 244 women (147 with PCOS and all 3 diagnostic features and 97 controls). Somalogic proteomic analysis was undertaken for the following complement system proteins: C1q, C1r, C2, C3, C3a, iC3b, C3b, C3d, C3adesArg, C4, C4a, C4b, C5, C5a, C5b-6 complex, C8, properdin, Factor B, Factor D, Factor H, Factor I, Mannose-binding protein C (MBL), Mannan-binding lectin serine protease 1 (MASP3), Complement decay-accelerating factor (DAF) and Complement factor H-related protein 5 (CFHR5). Results The alternative pathway of the complement system was primarily activated in PCOS, with increased C3 (p<0. 05), properdin and Factor B (p<0. 01). In addition, inhibition of this pathway was also seen in PCOS, with increase in CFHR5, Factor H and Factor I (p<0. 01). There were also increases in the downstream complement factors of iC3b and C3d, associated with an enhanced B cell response, and C5a, associated with inflammatory cytokine release (p<0. 01). Conclusion This is the most comprehensive evaluation of the complement system in PCOS to date and reveals upregulation of the alternative complement system that appears to be offset by the concurrent upregulation of its inhibitors. However, any additional dysregulation of the system, such as occurs with COVID19 infection, may give rise to an increased risk for clotting in women with PCOS. Presentation: No date and time listed" @default.
- W4308133723 created "2022-11-08" @default.
- W4308133723 creator A5008114754 @default.
- W4308133723 creator A5011785454 @default.
- W4308133723 date "2022-11-01" @default.
- W4308133723 modified "2023-09-26" @default.
- W4308133723 title "ODP064 Latrogenic Cushing Syndrome after Concomitant Oral Controlled-Release Budesonide and Famotidine Therapy" @default.
- W4308133723 doi "https://doi.org/10.1210/jendso/bvac150.143" @default.
- W4308133723 hasPublicationYear "2022" @default.
- W4308133723 type Work @default.
- W4308133723 citedByCount "0" @default.
- W4308133723 crossrefType "journal-article" @default.
- W4308133723 hasAuthorship W4308133723A5008114754 @default.
- W4308133723 hasAuthorship W4308133723A5011785454 @default.
- W4308133723 hasBestOaLocation W43081337232 @default.
- W4308133723 hasConcept C111684460 @default.
- W4308133723 hasConcept C126322002 @default.
- W4308133723 hasConcept C134018914 @default.
- W4308133723 hasConcept C14356644 @default.
- W4308133723 hasConcept C170493617 @default.
- W4308133723 hasConcept C179369057 @default.
- W4308133723 hasConcept C182629451 @default.
- W4308133723 hasConcept C185592680 @default.
- W4308133723 hasConcept C191590540 @default.
- W4308133723 hasConcept C203014093 @default.
- W4308133723 hasConcept C2775960820 @default.
- W4308133723 hasConcept C2777391703 @default.
- W4308133723 hasConcept C2779306644 @default.
- W4308133723 hasConcept C2780806702 @default.
- W4308133723 hasConcept C3018442814 @default.
- W4308133723 hasConcept C71318922 @default.
- W4308133723 hasConcept C71924100 @default.
- W4308133723 hasConcept C7407320 @default.
- W4308133723 hasConcept C8487232 @default.
- W4308133723 hasConcept C8891405 @default.
- W4308133723 hasConcept C90582226 @default.
- W4308133723 hasConceptScore W4308133723C111684460 @default.
- W4308133723 hasConceptScore W4308133723C126322002 @default.
- W4308133723 hasConceptScore W4308133723C134018914 @default.
- W4308133723 hasConceptScore W4308133723C14356644 @default.
- W4308133723 hasConceptScore W4308133723C170493617 @default.
- W4308133723 hasConceptScore W4308133723C179369057 @default.
- W4308133723 hasConceptScore W4308133723C182629451 @default.
- W4308133723 hasConceptScore W4308133723C185592680 @default.
- W4308133723 hasConceptScore W4308133723C191590540 @default.
- W4308133723 hasConceptScore W4308133723C203014093 @default.
- W4308133723 hasConceptScore W4308133723C2775960820 @default.
- W4308133723 hasConceptScore W4308133723C2777391703 @default.
- W4308133723 hasConceptScore W4308133723C2779306644 @default.
- W4308133723 hasConceptScore W4308133723C2780806702 @default.
- W4308133723 hasConceptScore W4308133723C3018442814 @default.
- W4308133723 hasConceptScore W4308133723C71318922 @default.
- W4308133723 hasConceptScore W4308133723C71924100 @default.
- W4308133723 hasConceptScore W4308133723C7407320 @default.
- W4308133723 hasConceptScore W4308133723C8487232 @default.
- W4308133723 hasConceptScore W4308133723C8891405 @default.
- W4308133723 hasConceptScore W4308133723C90582226 @default.
- W4308133723 hasIssue "Supplement_1" @default.
- W4308133723 hasLocation W43081337231 @default.
- W4308133723 hasLocation W43081337232 @default.
- W4308133723 hasOpenAccess W4308133723 @default.
- W4308133723 hasPrimaryLocation W43081337231 @default.
- W4308133723 hasRelatedWork W2026695565 @default.
- W4308133723 hasRelatedWork W2034760871 @default.
- W4308133723 hasRelatedWork W2888961943 @default.
- W4308133723 hasRelatedWork W2908785887 @default.
- W4308133723 hasRelatedWork W3128285708 @default.
- W4308133723 hasRelatedWork W3146642348 @default.
- W4308133723 hasRelatedWork W4220739615 @default.
- W4308133723 hasRelatedWork W4306152312 @default.
- W4308133723 hasRelatedWork W4308132842 @default.
- W4308133723 hasRelatedWork W4308133723 @default.
- W4308133723 hasVolume "6" @default.
- W4308133723 isParatext "false" @default.
- W4308133723 isRetracted "false" @default.
- W4308133723 workType "article" @default.